Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

Historic Non-Current Deferred Tax Liability for InMed Pharmaceuticals (INM) over the last 3 years, with Q2 2025 value amounting to $20000.0.

  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability changed N/A to $20000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $20000.0, marking a year-over-year change of. This contributed to the annual value of $20000.0 for FY2025, which is N/A changed from last year.
  • Per InMed Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $20000.0 for Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $211266.0 in Q2 2023 and a low of $20000.0 during Q2 2025
  • For the 3-year period, InMed Pharmaceuticals' Non-Current Deferred Tax Liability averaged around $101024.0, with its median value being $71806.0 (2022).
  • The largest annual percentage gain for InMed Pharmaceuticals' Non-Current Deferred Tax Liability in the last 5 years was 19421.78% (2023), contrasted with its biggest fall of 19421.78% (2023).
  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $71806.0 in 2022, then surged by 194.22% to $211266.0 in 2023, then plummeted by 90.53% to $20000.0 in 2025.
  • Its Non-Current Deferred Tax Liability stands at $20000.0 for Q2 2025, versus $211266.0 for Q2 2023 and $71806.0 for Q2 2022.